Want to see ABT full AI Analyst Report?
ABT Stock Chart & Stats
$103.06
$2.31(2.29%)
At close: 4:00 PM EDT
$103.06
$2.31(2.29%)
Day’s Range― - ―
52-Week Range$81.97 - $137.49
Previous CloseN/A
Volume10.37M
Average Volume (3M)13.15M
Market Cap
$201.83B
Enterprise Value$185.82K
Total Cash (Recent Filing)$5.60B
Total Debt (Recent Filing)$32.61B
Price to Earnings (P/E)37.5
Beta0.11
Next Earnings
Oct 21, 2026EPS Estimate
1.42Next Dividend Ex-DateN/A
Dividend Yield2.13%
Share Statistics
EPS (TTM)3.11
Shares Outstanding1,730,383,300
10 Day Avg. Volume14,994,333
30 Day Avg. Volume13,149,862
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$123.21Price Target Upside19.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)5.52
Revenue Forecast (FY)$50.31B
Bulls Say, Bears Say
Bulls Say
Diversified Revenue GrowthAbbott’s diagnostics, devices, nutrition and pharmaceuticals portfolio supports durable growth across multiple healthcare markets. This diversification reduces reliance on any single product cycle and provides resilience as demand shifts between segments.
Strong Cash GenerationRobust and growing free cash flow gives Abbott capacity to fund research, product launches, acquisitions and shareholder returns. Free cash flow also tracks earnings closely, supporting confidence that reported profitability converts into usable cash.
Innovation And Product PipelineAbbott continues investing in high-growth medical technologies, including diabetes monitoring, electrophysiology and structural heart devices. Regulatory milestones and new launches can extend its installed base, recurring consumables revenue and competitive relevance.
Bears Say
Higher Balance-Sheet LeverageThe sharp increase in debt reduces financial flexibility compared with Abbott’s prior position. Although equity remains substantial, higher obligations make the company more dependent on sustained cash generation and could constrain investment or capital returns.
Margin CompressionAbbott remains profitable, but recent margin normalization indicates that earnings growth may not fully match revenue growth. Persistent cost pressure, product mix changes or weaker businesses could limit operating leverage and reduce the durability of future profit expansion.
Ongoing Formula LitigationThe settlement removes some uncertainty but does not resolve Abbott’s broader preterm-formula litigation exposure. Remaining claims could create additional cash costs, management distraction and reputational pressure, particularly within the nutrition franchise.
Abbott Laboratories News
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was $81.97 and its highest was $137.49 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is $201.83B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 21, 2026 which is in 59 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 16, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.277 by $0.033.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 2.13%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.42.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,730,383,300 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of $1.31 in its last earnings report, beating expectations of $1.277. Following the earnings report the stock price went up 10.709%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in ABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.21 (19.56% Upside)
$123.21 (19.56% Upside)
Blogger Sentiment
Bullish
ABT Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $468.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.51%
12-Months-Change
Fundamentals
Return on Equity
2.13%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
ABT Company Deck
ABT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.View all ABT earnings summariesABT Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other
ABT Stock 12 Month Forecast
Average Price Target
$123.21
▲(19.56% Upside)
Technical Analysis
Ownership Overview
0.48% Insiders
23.90% Mutual Funds
16.51% Other Institutional Investors
33.57% Public Companies and Individual Investors